Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Purpose. To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH). Materials and Methods. Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of...

Full description

Saved in:

Bibliographic Details
Main Authors:	René Arnouk, Carlos Henrique Suzuki Bellucci, Roberto Benatuil Stull, José de Bessa Junior, Cesar Augusto Malave, Cristiano Mendes Gomes
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/2012/463574
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
by: Yoshizo Matsuka, et al.
Published: (2012-01-01)

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia
by: Yu Tong, et al.
Published: (2020-01-01)

Blockade of Glutamate Release by Botulinum Neurotoxin Type A in Humans: A Dermal Microdialysis Study
by: Larissa Bittencourt da Silva, et al.
Published: (2014-01-01)

New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A
by: Marina Vladimirovna Silkina, et al.
Published: (2024-07-01)

Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia
by: Wei Jin, et al.
Published: (2020-01-01)

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects
by: Marina Zamuner, et al.
Published: (2014-01-01)

Long-Term Followup after Electrocautery Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia
by: F. Kallenberg, et al.
Published: (2011-01-01)

Predictive Model for Estimating Prostate Resection Size in Transurethral Resection of the Prostate for Patients with Benign Prostatic Hyperplasia
by: Okwudli C. Amu, et al.
Published: (2024-07-01)

Development of a Cell-Based Functional Assay for the Detection of Clostridium botulinum Neurotoxin Types A and E
by: Uma Basavanna, et al.
Published: (2013-01-01)

Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990–2021
by: Saeid Safiri, et al.
Published: (2025-02-01)

Urinary Catheter Colonization by Multidrug-Resistant Cedecea neteri in Patient with Benign Prostatic Hyperplasia
by: Peter S. Ginn, et al.
Published: (2018-01-01)

PHARMACOTHERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA IN THE ABSENCE OF RISK OF DISEASE PROGRESSION
by: A. A. Kamalov, et al.
Published: (2018-03-01)

Intraprostatic Injection of Alcohol Gel for the Treatment of Benign Prostatic Hyperplasia: Preliminary Clinical Results
by: Benjamin T. Larson, et al.
Published: (2006-01-01)

Botulinum Neurotoxin Application to the Severed Femoral Nerve Modulates Spinal Synaptic Responses to Axotomy and Enhances Motor Recovery in Rats
by: Marcel Irintchev, et al.
Published: (2018-01-01)

Thulium laser enucleation of the prostate plus thulium fiber laser therapy for benign prostatic hyperplasia combined with bladder stones
by: Chen Wang, et al.
Published: (2024-08-01)

Development of a Recombinant Fusion Vaccine Candidate Against Lethal <i>Clostridium botulinum</i> Neurotoxin Types A and B
by: Eun-Sun Choi, et al.
Published: (2025-01-01)

Beyond the Comfort Zone: Strenuous Sports as a Preventive Tactic Against Benign Prostatic Hyperplasia
by: Wei Zhang, et al.
Published: (2025-02-01)

Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
by: Bilal Chughtai, et al.
Published: (2021-05-01)

Rauwolfia vomitoria- a promising medical plant for benign prostatic hyperplasia management; yet with challenges
by: George Awuku Asare, et al.
Published: (2025-02-01)

Comprehensive RNA-seq analysis of benign prostatic hyperplasia (BPH) in rats exposed to testosterone and estradiol
by: Xiao-Hu Tang, et al.
Published: (2025-01-01)

Management of perianesthesia in benign prostate hyperplasia patients with transvesica prostatectomy and uncontrolled hypertension: A case report
by: Suandika Made, et al.
Published: (2025-01-01)

Associations among immunophenotype, plasma metabolites, and benign prostatic hyperplasia: a mediation Mendelian randomization study
by: FAN Jiuming, et al.
Published: (2025-01-01)

Association of a Common Variant at 10q26 and Benign Prostatic Hyperplasia Aggressiveness in Han Chinese Descent
by: Xin Gu, et al.
Published: (2013-01-01)

A Systematic Review of Medical Treatments for Benign Prostatic Hyperplasia in Dogs: Evaluating Strategies for Reproductive Function Preservation
by: Florin Petrișor Posastiuc, et al.
Published: (2025-01-01)

A cross-tissue transcriptome-wide association study identifies new susceptibility genes for benign prostatic hyperplasia
by: Li Wang, et al.
Published: (2025-01-01)

Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma
by: Ayodele Alaiya, et al.
Published: (2000-01-01)

Prostatic Stromal Hyperplasia with Atypia
by: Ryan C. Hutchinson, et al.
Published: (2013-01-01)

Bladder Neck Contracture after Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia Treated with a Thermo-Expandable Metal Stent (Memokath® 045)
by: Jan Wen, et al.
Published: (2018-01-01)

Retracted: Evaluation and Correlation Analysis of Mental and Psychological Factors and Premature Ejaculation in Patients with Benign Prostatic Hyperplasia in Mobile Medical System
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia
by: Li Ruan, et al.
Published: (2015-01-01)

The Effect of Different Doses of Botulinum Toxin on Masseter Muscle in Patients with Bruxism.
by: Kawa F. Dizaye, et al.
Published: (2022-02-01)

WATER versus WATER II 5‐year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates
by: Mohamad Baker Berjaoui, et al.
Published: (2024-11-01)

Retracted: Risk Factors of Urinary Pathogenic Bacteria Infection after Benign Prostatic Hyperplasia Surgery and Curative Effect Analysis of Shuangdong Capsule Intervention
by: Emergency Medicine International
Published: (2024-01-01)

The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study
by: Kiyohide Fujimoto, et al.
Published: (2013-01-01)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
by: Yoshinori Tanaka, et al.
Published: (2017-01-01)

Combined extracts of Syzygium aromaticum (Clove) and Xylopia aethiopica (Negro pepper) seeds inhibit testosterone propionate-induced benign prostatic hyperplasia in Wistar rats
by: Emmanuel Nnaemeka Uhuo, et al.
Published: (2024-12-01)

Association between Chinese visceral adiposity index and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a national cohort study
by: Kunhui Chang, et al.
Published: (2025-01-01)

Prostatic hyperplasia and congenital bladder diverticulum. A case report
by: Ciro Esteban Delgado Cantero, et al.
Published: (2011-04-01)

Comprehensive Insight of Neurodegenerative Diseases and The Role of Neurotoxin Agents — Glutamate
by: Hui-Min Yap, et al.
Published: (2020-04-01)

Patient-centred evaluation of a reduced dose of botulinum toxin A in the management of myofascial pain
by: Alice Cameron, et al.
Published: (2025-03-01)